Hormonal contraceptives and venous thromboembolism: An epidemiological update

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 27, Issue 1, 2013, Pages 25-34

  Plu Bureau, Genevieve ^a,b   Maitrot Mantelet, Lorraine ^a   Hugon Rodin, Justine ^a   Canonico, Marianne ^b,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

hemostasis; hormonal contraceptives; progestin only pill; venous thromboembolism

Indexed keywords

CONTRACEPTIVE AGENT; CYPROTERONE ACETATE; DESOGESTREL; DROSPIRENONE; ESTRADIOL PLUS NOMEGESTROL ACETATE; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETONOGESTREL; GESTAGEN; GESTODENE; LEVONORGESTREL; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DEEP VEIN THROMBOSIS; DRUG DOSE REDUCTION; DRUG FORMULATION; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; LOW DRUG DOSE; LUNG EMBOLISM; MEDLINE; ORAL CONTRACEPTION; PILL; SYSTEMATIC REVIEW; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

EID: 84873399304     PISSN: 1521690X     EISSN: 15321908     Source Type: Journal    
DOI: 10.1016/j.beem.2012.11.002     Document Type: Review

References (71)

1. E. Oger for the EPI-GETBO Stud Group Incidence of venous thromboembolism: a community-based study in Western France Thrombosis and Haemostasis 83 2000 657 660
2. I.A. Naess, S.C. Christiansen, and P. Romundstad Incidence and mortality of venous thrombosis: a population-based study Journal of Thrombosis and Haemostasis 4 2007 692 699
3. Ø. Lidegaard, E. Løkkegaard, and A.L. Svendsen Hormonal contraception and risk of venous thromboembolism: national follow-up study British Medical Journal 339 2009 b2890
4. Ø. Lidegaard, L.H. Nielsen, and C.W. Skovlund Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9 British Medical Journal 343 2011 d6423
5. FDA. Combined hormonal contraceptives (CHCs) and the risk of cardiovascular disease endpoints, final report 111022v2. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf.
6. J. Bitzer, and J.A. Simon Current issues and available options in combined hormonal contraception Contraception 84 2011 342 356
7. R. Sitruk-Ware New progestagens for contraceptive use Human Reproduction Update 12 2006 169 178
8. R. Sitruk-Ware, and A. Nath The use of newer progestins for contraception Contraception 82 2010 410 417
9. R.A. Edgren, and F.Z. Stanczyk Nomenclature of the gonane progestins Contraception 60 1999 313
10. Kl Whalen, and R. Rose Estradiol valerate/dienogest: a novel oral contraceptive Annals of Pharmacotherapy 45 2011 1256 1261
11. A.O. Mueck, and R. Sitruk-Ware Nomegestrol acetate, a novel progestogen for oral contraception Steroids 76 2011 531 539
12. N. Chabbert-Buffet, D. Chassard, and E. Ochsenbein Inhibition of ovulation by NOMAC/E2, a novel monophasic oral contraceptive combining nomegestrol acetate and 17β-oestradiol: a double-blind, randomised, dose-finding pilot study European Journal of Contraception and Reproductive Health Care 16 2011 76 84
13. D.A. Grimes, L.M. Lopez, and P.A. O'Brien Progestin-only pills for contraception Cochrane Database of Systemic Review 1 2010 Jan 20 CD007541
14. B.B. Gerstman, J.M. Piper, and J.P. Freiman Oral contraceptives oestrogen and progestin potencies and the incidence of deep venous thromboembolism American Journal of Epidemiology 133 1991 32 37
15. J.M. Kemmeren, A. Algra, and D.E. Grobbee Third generation oral contraceptives and risk of venous thrombosis: meta-analysis British Medical Journal 323 2001 1 9
16. F. Martinez, I. Ramirez, and E. Perez-Campos Venous and pulmonary thromboembolism and combined hormonal contraceptives. Systematic review and meta-analysis European Journal of Contraception and Reproductive Health Care 17 2012 7 29
17. M. Canonico, G. Plu-Bureau, and G.D. Lowe Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis British Medical Journal 336 2008 1227 1231
18. P. Gaussem, M. Alhenc-Gelas, and J.L. Thomas Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17β-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised study Journal of Thrombosis and Haemostasis 105 2011 560 567
19. U.M. Agren, M. Anttila, and K. Mäenpää-Liukko Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism European Journal of Contraception and Reproductive Health Care 16 2011 444 457
20. R.M. Herings, J. Urquhart, and H.G. Leufkens Venous thromboembolism among new users of different oral contraceptibes Lancet 354 1999 127 128
21. R.D.T. Farmer, T.J. Williams, and E.L. Simpson Effect of 1995 pill scare on rates of venous thromboembolism among women taking combined oral contraceptives: analysis of General Practice Research Database British Medical Journal 321 2000 477 479
22. M.A. Lewis, K.D. MacRae, and D. Kühl-Habich The differential risk of oral contraceptives: the impact of full exposure history Human Reproduction 14 1999 1493 1499
23. K.W.M. Bloemenkamp, F.R. Rosendaal, and H.R. Buller Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained b diagnostic suspicion and referral bias Archives of Internal Medicine 159 1999 65 70
24. O. Lidegaard, B. Edstrom, and B. Kreiner Oral contraceptives and venous thromboembolism: a five-year national case-control stud Contraception 65 2002 187 196
25. A. van Hylckama Vlieg, F.M. Helmerhorst, and J.P. Vandenbroucke The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study British Medical Journal 339 2009 b2921
26. K.W. Bloemenkamp, F.R. Rosendaal, and F.M. Helmerhorst Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen Lancet 346 1995 1593 1596
27. H. Jick, S.S. Jick, and V. gurewich Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components Lancet 346 1995 1589 1593
28. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease Lancet 346 1995 1582 1588
29. N.R. Poulter for World Health Organization Venous thromboembolic disease and combined oral contraceptives: results of international case-control study Lancet 346 1995 1575 1582
30. W.O. Spitzer, M.A. Lewis, and L.A.J. Heinemann Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study British Medical Journal 312 1996 83 88
31. F. Grodstein, M.J. Stampfer, and S.Z. Goldhaber Prospective study of exogenous hormones and risk of pulmonary embolism in women Lancet 348 1996 983 987
32. R.D.T. Farmer, R.A. Lawrenson, and C.R. Thompson Population based study of risk of venous thromboembolism associated with various oral contraceptives Lancet 349 1997 83 88
33. R.D. Farmer, J.C. Todd, and M.A. Lewis The risks of venous thromboembolic disease among German women using oral contraceptives: a database study Contraception 57 1998 67 70
34. R.D.T. Farmer, R.A. Lawrenson, and J.C. Todd Oral contraceptives and venous thromboembolic disease. Analyses of the UK General Practice Research Database and the UK Mediplus Database Human Reproduction Update 5 1999 688 706
35. S.S. Jick, J.A. Kaye, and S. Russmann Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel Contraception 73 2006 566 570
36. J.D. Seeger, J. Loughlin, and M. Eng Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives Obstetrics and Gynecology 110 2007 587 593
37. J.C. Dinger, L.A.J. Heinemann, and D. Kühl-Habich The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance study on oral contraceptives based on 142,475 women years of observation Contraception 75 2007 344 354
38. S.S. Jick, and R.K. Hernandez Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data British Medical Journal 340 2011 d2151
39. L. Parkin, K. Sharples, and R.K. Hernandez Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database British Medical Journal 340 2011 d2139
40. N. Gronich, I. Lavi, and G. Rennert Higher risk of venous thrombosis associated with drospirénone-containing oral contraceptives: a population-based cohort study Canadian Medical Association Journal 183 2011 E1319 E1325
41. L. Parkin, D.C.G. Skegg, and M. Wilson Oral contraceptives and fatal pulmonary embolism Lancet 355 2000 2133 2134
42. C. Vasilakis-Scaramozza, and H. Jick Risk of venous thromboembolism with cyproterone and levonorgestrel contraceptives Lancet 358 2001 1427 1429
43. H.E. Seaman, C.S. de Vries, and R.D.T. Farmer Venous thromboembolism associated with cyproterone acetate in combination with ethinyloestradiol (Dianette): observational studies using the UK General Practice Research Database Pharmacoepidemiology and Drug Safety 13 2004 427 436
44. T.W. Meade, G. Greenberg, and S.G. Thompson Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-microgram oestrogen preparations British Medical Journal 280 1980 1157 1161
45. A. van Hylckama Vlieg, and S. Middeldorp Hormone therapies and venous thromboembolism: where are we now? Journal of Thrombosis and Haemostasis 9 2011 257 266
46. G. Plu-Bureau, J. Amiral, and L. Guize Safety of combined oral contraceptives containing pills Lancet 347 1996 549
47. M. Alhenc-Gelas, G. Plu-Bureau, and S. Guillonneau Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives Journal of Thrombosis and Haemostasis 2 2004 1594 1600
48. J.M. Kemmeren, A. Algra, and J.C. Meijers Effect of second-and third-generation oral contraceptives on the protein C system in the absence or presence of the factor V Leiden mutation: a randomized trial Blood 103 2004 927 933
49. J. Rosing, S. Mideldorp, and J. Curvers Low-dose oral contraceptives and acquired resistance to activated protein-C: a randomised cross-over study Lancet 97 1999 2036 2040
50. V. Odlin, I. Milsom, and I. Persson Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstetricia et Gynecologica Scandinavica 81 2002 482 490
51. M. Raps, F. Helmerhorst, and K. Fleischer Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives Journal of Thrombosis and Haemostasis 10 2012 992 997
52. S.S. Jick, J.A. Kaye, and S. Russmann Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 μg of ethinyl estradiol Contraception 73 2006 223 228
53. S. Jick, J.A. Kaye, and L. Li Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 μg of ethinyl estradiol Contraception 76 2007 4 7
54. ® and venous thromboembolism: an update Contraception 81 2010 452 453
55. J.A. Cole, H. Norman, and M. Doherty Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users Obstetrics and Gynecology 109 2007 339 346
56. D.D. Dore, H. Norman, and J. Loughlin Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users Contraception 81 2010 408 413
57. O. Lidegaard, L. Hougaard-Nielsen, and C. Wessel-Skovlund Venous thrombosis in users of non-oral hormonal contraception: follow-up, Denmark 2001-10 British Medical Journal 344 2012 e2990
58. R. Sitruk-Ware, G. Plu-Bureau, and J. Menard Effects of oral and transvaginal on hemostatic factors and hepatic proteins in a randomised cross-over study Journal of Clinical Endocrinology and Metabolism 92 2007 2074 2079
59. K. Fleischer, H.A. van Vliet, and F.R. Rosendaal Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: a cross-over study Thrombosis Research 3 2009 429 435
60. H.A. Van Vliet, F.R. Rosendaal, and K. Fleischer Effects of the contraceptive vaginal ring, the contraceptive transdermal patch and combined oral contraceptives on markers of hemostasis Contraception 1 2010 88 89
61. C. Kluft, P. Meijer, and K.D. LaGuardia Comparison of a transdermal contraceptive patch vs. oral contraceptives on hemostasis variables Contraception 77 2008 77 83
62. A. Bergandal, V. Odlind, and I. Persson Acta Obstetrica Gynecologica 88 2009 261 266
63. M.A. Blanco-Molina, M. Lozano, and A. Cano Progestin-only contraception and venous thromboembolism Thrombosis Research 129 2012 257 262
64. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization Collaborative study of cardiovascular disease and steroid hormone contraception Contraception 57 1998 315 324
65. A. van Hylckama Vlieg, F.M. Helmerhorst, and F.R. Rosendaal The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device Areteriosclerosis, Thrombosis and Vascular Biology 30 2010 2297 2300
66. J.P. Vandenbroucke, T. Koster, and E. Briet Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation Lancet 334 1994 1453 1457
67. O. Wu, L. Robertson, and P. Langhorne Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The thrombosis: risk and economic assessment of Thrombophilia Screening (TREATS) study Thrombosis and Haemostasis 94 2005 17 25
68. J. Conard, G. Plu-Bureau, and N. Bahi Progestogen-onl contraception in women at high risk of venous thromboembolism Contraception 70 2004 437 441
69. H. Vaillant-Roussel, L. Ouchchane, and C. Dauphin Risk factors for recurrence of venous thromboembolism associated with the use of oral contraceptives Cpontraception 84 2011 23 30
70. N. Chabbert-Buffet, Z. Amoura, and P.Y. Scarabin Pregnane progestin contraception in systemic lupus erythematossus: a longitudinal study of 187 patients Contraception 83 2011 229 237
71. M. Abdollahi, M. Cushman, and F. Rosendaal Obesity: risk of venous thrombosis and the interaction with coagulation factors levels and oral contraceptive use Thrombosis and Haemostasis 89 2003 493 498